Figure 6
Treatment with BD750-treated DC ameliorates EAE. C57BL/6 mice were immunized with MOG35-55 peptide in CFA and PTX. (A) The mice were randomized and treated intravenously with 20 µM BD750 pretreated DC (12 h) loaded with MOG35_55 on d 7, 11 and 15 post the first PTX injection. Data are shown as the mean ± SEM of each group (n = 8 per group), *P < 0.05 versus the PBS group. (B) The EAE mice were treated intravenously with 20 µM BD750-treated DCs loaded with or without MOG35-55 on d 7, 11 and 15 post the first PTX injection. Data are shown as the mean ± SEM of each group (n = 8 per group). *P < 0.05 versus the DC (20 µM BD750) without MOG35-55 loading group. (C) The EAE mice were treated intravenously with 20 µM BD750-treated DCs loaded with MOG35-55 on d 7, 11 and 15 or delayed on 19, 23 and 27 d or earlier on d −2, 2 and 6 post the first PTX injection. Data are shown as the mean ± SEM of each group (n = 8 per group). *P < 0.05 versus the tolDC intravenous (dpi 19, 23 and 27) group. (D) The EAE mice were treated intravenously with 20µM BD750-treated DC loaded with MOG35-55 on d 7, 11 and 15 post induction only for 1–2 times. Data are shown as the mean ± SEM of each group (n = 8 per group). *P < 0.05 versus the tolDC intravenous (dpi 7) group. The dynamic progression of EAE in individual groups of mice was monitored daily by two researchers without knowing the groups in a Plinded manner, and some mice from some groups of mice were euthanized at 22 d post induction for analysis of inflammation and demyelination in the spinal cord tissues. (E) Histological examinations, Arrows indicate inflammatory infiltrates. Scale Par, 100µm (magnification 100 ×).